Dr Reddy’s Lab Rises Over 3% After Srikakulam Facility Clears USFDA

Drug firm Dr Reddy's Laboratories share on Monday rose 3.1% on an intraday basis as the company on Friday said the US health regulator has completed an inspection of its Srikakulam facility without making any observations.

The stock on the BSE hit an intraday high of Rs 2721 per share and an intraday low of Rs 2691 per share on the BSE.

The stock has delivered negative returns of over 13% in a period of one year and has underperformed the  BSE Sensex and  BSE Healthcare indices over the same time span.

Dr Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.